Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

The Bronchiectasis and NTM Research Registry investigators

doi:10.1093/cid/ciac788

Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

The Bronchiectasis and NTM Research Registry investigators

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.

Original language	English (US)
Pages (from-to)	338-341
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	76
Issue number	2
DOIs	https://doi.org/10.1093/cid/ciac788
State	Published - Jan 15 2023
Externally published	Yes

Keywords

Mycobacterium abscessus
Mycobacterium avium complex
adverse effects
antibiotic treatment
nontuberculous mycobacterial infection

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciac788

Fingerprint

Dive into the research topics of 'Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines'. Together they form a unique fingerprint.

Cite this

The Bronchiectasis and NTM Research Registry investigators (2023). Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clinical Infectious Diseases, 76(2), 338-341. https://doi.org/10.1093/cid/ciac788

Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. / The Bronchiectasis and NTM Research Registry investigators.
In: Clinical Infectious Diseases, Vol. 76, No. 2, 15.01.2023, p. 338-341.

Research output: Contribution to journal › Article › peer-review

The Bronchiectasis and NTM Research Registry investigators 2023, 'Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines', Clinical Infectious Diseases, vol. 76, no. 2, pp. 338-341. https://doi.org/10.1093/cid/ciac788

The Bronchiectasis and NTM Research Registry investigators. Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clinical Infectious Diseases. 2023 Jan 15;76(2):338-341. doi: 10.1093/cid/ciac788

The Bronchiectasis and NTM Research Registry investigators. / Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry : Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. In: Clinical Infectious Diseases. 2023 ; Vol. 76, No. 2. pp. 338-341.

@article{a69dca2c4d0c454a97c1a123799f6c2a,

title = "Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines",

abstract = "Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.",

keywords = "Mycobacterium abscessus, Mycobacterium avium complex, adverse effects, antibiotic treatment, nontuberculous mycobacterial infection",

author = "{The Bronchiectasis and NTM Research Registry investigators} and Ku, {Jennifer H.} and Emily Henkle and Aksamit, {Timothy R.} and Alan Barker and Brunton, {Amanda E.} and Winthrop, {Kevin L.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2023",

month = jan,

day = "15",

doi = "10.1093/cid/ciac788",

language = "English (US)",

volume = "76",

pages = "338--341",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry

T2 - Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

AU - The Bronchiectasis and NTM Research Registry investigators

AU - Ku, Jennifer H.

AU - Henkle, Emily

AU - Aksamit, Timothy R.

AU - Barker, Alan

AU - Brunton, Amanda E.

AU - Winthrop, Kevin L.

PY - 2023/1/15

Y1 - 2023/1/15

N2 - Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.

AB - Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.

KW - Mycobacterium abscessus

KW - Mycobacterium avium complex

KW - adverse effects

KW - antibiotic treatment

KW - nontuberculous mycobacterial infection

UR - http://www.scopus.com/inward/record.url?scp=85146364341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146364341&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac788

DO - 10.1093/cid/ciac788

M3 - Article

C2 - 36134755

AN - SCOPUS:85146364341

SN - 1058-4838

VL - 76

SP - 338

EP - 341

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this